With a biologics license application pending for the psoriasis drug Raptiva (efalizumab) at the FDA, Genentech Inc. and Serono SA said they are expanding their overseas development and marketing agreement to add 15 Asian companies to an existing deal that covered Europe. (BioWorld Today)
TORONTO - There's a reason why the government of Victoria in Melbourne, Australia, is co-sponsoring numerous sessions at BIO 2002 on doing business globally. It's the same reason Canada Minister of Industry Allan Rock spoke at a plenary luncheon on Monday, and why Toronto is the host city for this year's conference.
In a move that seemed to surprise few industry observers, Bristol-Myers Squibb Co. said it wants to restructure the potential $2 billion deal with ImClone Systems Inc. regarding the FDA-stalled Erbitux (cetuximab) for colorectal cancer. (BioWorld Today)
